TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Te

TPST - Tempest announces development collaboration with senlang Biotechnology for tpst-4003, a cd7-targeted next-generation in vivo Car-t Tempest Therapeutics - first patient dosing for tpst-4003 trial expected in Q4 2026 - Co and senlang to develop tpst-4003 with trial in China for mg and MS